Network meta-analysis of Chinese patent medicine adjuvant treatment of poststroke depression

Ying Yu,Gong Zhang,Jing Liu,Tao Han,Hailiang Huang
DOI: https://doi.org/10.1097/md.0000000000021375
IF: 1.6
2020-07-31
Medicine
Abstract:<span><span class="ej-keyword">Poststroke depression</span> is one of the common complications of clinical cerebrovascular diseases. It is commonly seen in 3 to 6 months after the onset of stroke. The incidence rate is 22% to 75%. The patient not only has depression-related emotional symptoms, but also are accompanied by autonomic nervous disorders and other physical symptoms. It will also delay the recovery time of patients' neurological function, cognitive function, and limb function due to different degrees of depression, and even further aggravate the mortality and risk of accidental death of cerebrovascular disease. In recent years, <span class="ej-keyword">Chinese patent medicine</span> combined with western medicine has been widely used in the treatment of this disease. Many clinical practices have proved that the adjuvant treatment of pure Chinese herbal medicine can effectively alleviate the <span class="ej-keyword">poststroke depression</span> state and reduce the neurological deficits. The author has sorted out the relevant literature and data analysis to screen out the seven most representative and commonly used <span class="ej-keyword">Chinese patent medicine</span> preparations in clinical treatment of <span class="ej-keyword">poststroke depression</span>, which have certain clinical comparability when the dosage form and syndrome type are relatively unified. The <span class="ej-keyword">network meta-analysis</span> method is used to select the best clinical treatment plan, so as to provide reference value and evidence-based medicine evidence for the clinical optimization of drug selection.</span>
medicine, general & internal
What problem does this paper attempt to address?